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Background. The relationship among plasma brain natriuretic peptide (BNP), markers of
extracellular matrix (ECM) remodeling, and left ventricular (LV) dilation after reperfused
acute myocardial infarction is poorly known.
Methods and Results. Echocardiogram, plasma BNP, and ECM degradation markers (serum
amino-terminal telopeptide of type I procollagen and type III procollagen and carboxy-terminal
telopeptide of type I procollagen [ICTP]) were evaluated in 34 patients at days 1, 3, and 30 after first
reperfused acute myocardial infarction. At 1 month, infarct size and severity and LV volume were
measured by sestamibi gated single photon emission computed tomography. Patients were stratified
according to day 3 BNP levels into 2 groups: group 1 (n  17) had BNP values over the median value,
and group 2 (n  17) had BNP values under the median value. Infarct size and severity were similar
in the 2 groups. LV volumes increased in group 1 but decreased in group 2 (P < .01). BNP
values, LV volume/mass index, and infarct size were independent predictors of 1-month LV
dilation (  .58 [P  .001],   .41 [P  .01], and   .32 [P  .03], respectively). Levels of
serum amino-terminal propeptide of type I procollagen and type III procollagen were similar in
both groups. The level of ICTP increased significantly in group 1 only, and after 3 days, it was
higher (P < .01) than in group 2. In group 1 ICTP significantly interacted with the relationship
between BNP release and serial changes in LV volumes (F  4.87, P  .03).
Conclusions. ICTP is related to elevated BNP level independently of infarct size and severity
and interacts with the relationship between BNP and LV dilation. BNP levels could play a role
in LV remodeling by favoring ECM degradation. (J Nucl Cardiol 2008;15:644-54.)
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In patients with acute myocardial infarction (AMI),
plasma brain natriuretic peptide (BNP) levels rise
quickly, reaching a peak at approximately 16 hours after
admission, and then decline.1,2 Patients with large AMI
have higher BNP levels, showing a second peak of BNP
release (biphasic pattern) about 5 days after the onset of
symptoms.2 Sustained high BNP level early after AMI
has been shown to be a marker of left ventricular (LV)
remodeling and adverse prognosis.3,4 Experimental stud-
ies suggest that elevated BNP levels enhance extracellu-
lar matrix (ECM) degradation.5,6 ECM degradation plays
a key role in LV remodeling after AMI.7 Therefore sus-
tained high BNP level could be not just a simple marker but
also a modulator of the remodeling process by enhancing
ECM degradation. Studies in patients with postinfarction
LV remodeling suggest a relationship between BNP and
serum surrogate markers for ECM remodeling.8-10 So far,
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this relationship has been interpreted as a consequence of
their common association with infarct size.
Recently, we reported that patients in whom LV
remodeling developed after AMI had significantly higher
levels of BNP and carboxy-terminal telopeptide of type I
procollagen (ICTP), an ECM degradation product, than
patients without remodeling, and that this correlation was
independent of enzymatic and echocardiographic esti-
mates of infarct extent.11 The latter issue is crucial,
because demonstrating that, in patients with comparable
infarct dimensions, LV remodeling is present only in
association with high levels of BNP and serum products
of collagen metabolism would suggest their causative
role in the remodeling process. To support this conclu-
sion, it is mandatory to rely on an accurate infarct
measurement. The limitations of enzymatic and echocar-
diographic infarct estimates are well known.12-15 Con-
versely, it is widely accepted that technetium 99m
sestamibi single photon emission computed tomography
(SPECT) is a most reliable method for measuring infarct
size, with the additional advantage of assessing infarct
severity as well.16-19
Thus the primary aim of this study was to determine
whether sustained high BNP level early after AMI
(sustained BNP release) is related to a different temporal
profile of serum products of type I and type III procol-
lagen independently of infarct size and severity, as
assessed by Tc-99m sestamibi SPECT. A secondary aim
was to examine the relationship between sustained BNP
release after AMI, serum indices of collagen turnover,
and early LV remodeling.
METHODS
Patients and Study Protocol
We prospectively studied 34 patients with a first ST-
elevation AMI selected among 60 patients consecutively
admitted for emergency primary percutaneous coronary
intervention. Prior AMI was excluded based on history,
electrocardiogram, and echocardiographic pattern. Only pa-
tients with AMI and LV systolic dysfunction (left ventricular
ejection fraction [LVEF]40%)20 were considered eligible for
the study because of their increased risk of sustained BNP
release early after AMI.2 To avoid the potential confounding
effect of a residual stenosis/occlusion and/or suboptimal flow in
the infarct-related artery (IRA) on subsequent serum values of
collagen products,21 only patients in whom anterograde flow
was fully restored (Thrombolysis in Myocardial Infarction
grade 3 flow) without significant residual stenosis were in-
cluded in the study. Exclusion criteria were (1) cardiogenic
shock, (2) cardiac disease other than coronary artery disease,
(3) renal insufficiency (serum creatinine level 2.0 mg/dL),
(4) diseases potentially responsible for abnormal collagen
turnover (alcoholic liver disease, metabolic bone disease, hy-
perthyroidism, pulmonary fibrosis, and connective tissue dis-
orders), (5) life-limiting noncardiac disease, and (6) inadequate
echocardiographic image quality. Of the 60 potential candi-
dates for the study, 20 (33%) were excluded because of an
LVEF greater than 40%, 2 patients (3%) were excluded
because of inadequate quality of the echocardiographic images,
and an additional 2 patients (3%) did not adhere to the
follow-up protocol. Thus 36 patients were enrolled in the study.
During the first 3 days after index AMI, 2 patients (5%) died
from refractory congestive heart failure. Thus the final study
group consists of 34 patients. All patients underwent serial
controls including clinical status, echocardiography, and dos-
age of plasma BNP, carboxy-terminal propeptide of type I
procollagen (PICP), ICTP, and amino-terminal propeptide of
type III procollagen (PIIINP) at day 1, day 3, and month 1 after
index AMI. Furthermore, at 1 month after index AMI, resting
Tc-99m sestamibi gated SPECT was performed for the mea-
surement of myocardial infarct size and severity and of LV
volumes,19 and coronary angiography was performed for the
evaluation of IRA patency. The study protocol was approved
by the ethics committee of our institution, and all patients gave
written informed consent to participate in the study.
Echocardiography
Complete M-mode and 2-dimensional echocardiography
and Doppler ultrasound examinations were performed blindly
with a commercially available imaging system (Sonos 5500;
Hewlett-Packard, Palo Alto, Calif). Details pertaining to mo-
dality of acquisition and analysis of echocardiographic data, as
well as the agreement between LV volume index measurements
(intraobserver variability, r  0.96; interobserver variability,
r  0.94) in our laboratory, have been reported elsewhere.22,23
Measurement of BNP and Indices of Collagen
Metabolism
Blood samples were taken at least 30 minutes before
sampling, with the patient resting in a semirecumbent supine
position. For BNP measurement, blood samples were col-
lected into plastic tubes containing ethylenediaminetetraace-
tic acid and aprotinin (500 KIU/mL); the plasma was
separated by centrifugation at 2000g at 4°C and stored at
80°C until analysis. Plasma BNP level was measured by a
commercial immunoradiometric assay method (Shionoria
BNP; CIS Bio International, Milan, Italy). The minimum
sensitivity and upper limit of normal values were 2 and 18.4
pg/mL, respectively, for the BNP assay, with the highest
intra-assay and interassay coefficients of variation being
2.7% and 4.2%, respectively. For PICP, ICTP, and PIIINP
measurement, blood samples were collected into plastic
tubes without additives and the separated sera were stored at
80°C until analysis. PICP, ICTP, and PIIINP were mea-
sured by radioimmunoassay kits (Orion Diagnostica, Espoo,
Finland). The minimum sensitivity and upper limit of normal
values were 1.2 and 202 ng/mL, respectively, for the PICP
assay; 0.4 and 5.6 ng/mL, respectively, for ICTP; and 0.2
and 4.5 ng/mL, respectively, for PIIINP. The highest intra-
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assay and interassay coefficients of variation were 3.2% and
6.6%, respectively, for PICP; 9.4% and 9.0%, respectively,
for ICTP; and 1.7% and 5.3%, respectively, for PIIINP.
Gated SPECT
Gated SPECT acquisition began 60 minutes after Tc-99m
sestamibi injection (740 MBq), by use of a double-head camera
equipped with high-resolution collimators, with a 180° rotation
arc, 32 projections, 60 seconds per projection, 8 frames per
heart cycle, and 64  64 matrices. The studies were recon-
structed via filtered backprojection without attenuation or
scatter correction and realigned along the heart axis. Perfusion
defects were quantified as percentage of LV wall, with the
defect threshold set at 60% of peak uptake.19,24 Infarct severity,
as a measure of infarct transmurality, was defined as the lowest
ratio of minimal to maximal counts in the short-axis slices
evaluated for infarct size.18,19 LV end-diastolic volume and
end-systolic volume were measured by an automated and
validated method.25 Volumetric data were corrected for body
surface area and expressed as indices.
Definitions and Outcome Measures
Sustained BNP release during AMI was defined as the
presence of a plasma BNP value over the median value 3 days
after index AMI. The choice of the third day for the last
measurement of BNP levels during the early phase of AMI was
based on prior studies in the same setting showing that day 3 is
the optimal timing for the prognostic value of BNP.3,4 LV
dilation was defined as a change in left ventricular end-diastolic
volume index (LVEDVI) from baseline to 1 month (LVEDVI).
Statistical Analysis
Continuous data were expressed as mean  SEM, and
categorical data as frequencies. Continuous variables were tested
by unpaired t test once normality was demonstrated (Shapiro-
Wilk test); otherwise, a nonparametric test was used (Mann-
Whitney U test). Categorical variables were compared by the
2 or Fisher exact test when appropriate. Linear correlations were
tested by use of the Pearson correlation coefficient once normality
was demonstrated; otherwise, Spearman correlation was used. We
tested partial correlations between BNP and procollagens, control-
ling for SPECT measures of infarct size and severity. Analysis of
variance with the Bonferroni post hoc test and Friedman analysis
of variance were used to analyze changes in echocardiographic
measures (LV volumes, LVEF, and deceleration time of early
transmitral flow [DT]) and neurohormonal measures (BNP, ICTP,
PICP, and PIIINP), respectively, over time. Forward stepwise
linear multivariate regression analysis was used to evaluate the
predictors of change in LVEDVI from baseline to 1 month
(LVEDVI). The variables submitted to the stepwise procedure
were age, sex, symptom-to-balloon time, anterior infarct location,
pattern of BNP release, DT, LV volume–mass ratio, SPECT
infarct size, and SPECT infarct severity. Hierarchic multiple
regression analysis was performed to test the value of a clinical-
imaging model versus a clinical-serum model in predicting
1-month LV remodeling. Repeated-measures analysis was used to
evaluate the interaction of procollagens on the relationship be-
tween time course of LVEDVI and different pattern of BNP
release. P  .05 was considered statistically significant. All
statistical calculations were performed by use of SPSS for Win-
dows software (release 11.5; SPSS, Chicago, Ill).
RESULTS
Patient Characteristics
The patient clinical, echocardiographic, and therapeu-
tic data are shown in Table 1. Patients with sustained BNP
release during AMI (group 1, n  17) had a longer
symptom-to-balloon time, lower LVEF, and higher LV
volume/mass index than patients without sustained BNP
release (group 2, n  17). There were no significant
differences between groups regarding risk factors and drug
regimen. In the angiographic follow-up the IRA patency
rate was 100% in both groups. Moderate to severe mitral
regurgitation was registered in 3 patients in group 1 and 2 in
group 2.
Gated SPECT
One-month gated SPECT showed similar infarct
size and infarct severity in the 2 groups of patients
(23%  3% vs 19%  2% [P  .256] and 0.33  0.03
vs 0.40  0.02 [P  .158], respectively) (Figure 1).
Individual SPECT measures of infarct size and severity
are presented in Table 2. In the presence of similar
infarct size and severity, LVEDVI and left ventricular
end-systolic volume index (LVESVI) in group 1 were
significantly larger than those in group 2 (80  8 mL vs
61 4 mL [P .04] and 51 6 mL vs 35 3 mL [P
.04], respectively). A significant correlation was found
between SPECT measures of infarct severity and plasma
value of BNP at day 3 (r  0.36, P  .04) and at month
1 (r  0.56, P  .001).
Serial Changes in Echocardiographic LV Volumes
and Function
The changes in LVEDVI, LVESVI, and LVEF from
baseline to 1 month were significantly different between
groups (Figure 2). Individual values of 6-month LV
volumes and ejection fraction are presented in Table 2. A
significant relationship was found between concurrent
echocardiographic and SPECT measures of LV end-
diastolic volume and end-systolic volume (r 0.50, P
.003 for both).
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Figure 1. One-month gated SPECT infarct size and infarct severity in the 2 groups with and without
sustained plasma BNP release.
Table 1. Baseline clinical, echocardiographic, and therapeutic characteristics
All patients (n  34) Group 1 (n  17) Group 2 (n  17) P value
Age (y) 62 2 64 3 61 2 .24
Male (%) 28 (82) 14 (82) 14 (82) .99
Diabetes (%) 9 (27) 6 (35) 3 (17) .43
Hypertension (%) 17 (50) 6 (35) 11(65) .16
Anterior infarct location (%) 27 (79) 14 (82) 13 (77) .99
Multivessel disease (%) 11 (61) 11 (61) 5 (31) .10
Symptom-to-balloon time (h) 4.8 0.3 5.4 0.5 4.2 0.3 .04
Mass index (g/m2) 90  3 86 4 94 5 .34
Heart rate (beats/min) 77 3 81 3 72 4 .07
Systolic BP (mm Hg) 125 4 117 5 133 4 .06
LVEDVI (mL/m2) 58  2 60 4 56 3 .60
LVESVI (mL/m2) 37  2 40 2 34 2 .13
LV volume–mass ratio 0.60 0.03 0.73 0.03 0.58 0.04 .01
LVEF (%) 36 1 33 2 38 1 .02*
IZWMSI 2.3 0.07 2.4 0.06 2.3 0.05 .13*
DT (ms) 168 7 154 11 182 8 .08
E/A 0.9 0.07 1 0.1 0.9 0.07 .18*
BNP (pg/mL) 213 27 306 42 121 14 .01*
Aspirin 34 (100) 17 (100) 17 (100) .99
Thienopiridines 34 (100) 17 (100) 17 (100) .99
Statins 17 (50) 6 (35) 11 (65) .17
Loop diuretic 29 (85) 15 (88) 14 (82) .62
Spironolactone 12 (35) 6 (36) 5 (29) .66
ACE inhibitors 32 (94) 16 (94) 16 (94) .99
	-Blockers 5 (15) 1 (6) 4 (24) .33
Coronary stent 34 (100) 17 (100) 17 (100) .99
BP, Blood pressure; IZWMSI, infarct zone wall motion score index; DT, wave deceleration time of early transmitral flow; E/A, ratio between
peak flow velocities at rapid filling and at atrial contraction of transmitral flow; ACE, angiotensin-converting enzyme; BNP, brain natriuretic
peptide; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection
fraction.
*Variables for which nonparametric test was used.
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Serial Changes in Serum Products of Type I and
Type III Collagen
From baseline to month 1, PICP significantly (P .05)
increased in both groups with and without sustained BNP
release, and no significant differences in PICP and PIIINP
values were found between groups at each time point of
measurement (Figures 3A and 3C). ICTP significantly
increased from day 1 to month 1 in group 1 patients but
remained unchanged in group 2. Furthermore, since day 3,
serum ICTP was significantly (P  .01) higher in group 1
than in group 2 (Figure 3B). Individual serum values of type
I and type III procollagen at each time point of measure-
ment are presented in Table 2.









ICTP (ng/mL) PICP (ng/mL)
Day 1 Day 3 Month 1 Day 1 Day 3 Month 1
Group 1
1 192 34 0.10 7 12 9 57 106 95
2 190 0 0.75 4 5 5 84 114 62
3 177 5 0.42 3 4 4 107 114 160
4 207 30 0.19 2 7 11 134 102 122
5 206 12 0.49 5 7 7 106 137 187
6 297 38 0.11 3 6 4 63 85 96
7 866 9 0.29 13 16 9 124 197 194
8 259 20 0.30 3 6 4 151 92 177
9 909 8 0.49 4 11 3 130 58 118
10 221 37 0.22 6 8 6 93 111 85
11 194 38 0.41 2 4 2 49 81 98
12 161 24 0.43 9 6 8 109 167 143
13 270 21 0.36 4 6 5 95 88 119
14 296 28 0.24 4 6 5 99 79 100
15 212 40 0.21 7 7 4 83 91 133
16 668 22 0.42 10 13 9 103 144 132
17 219 36 0.26 5 5 9 42 122 159
Mean  SEM 326  58 23  3 0.33 0.03 5 0.7 8  0.8 6  0.6 96 7 111 9 128 9
Group 2
18 78 18 0.45 2 3 4 76 107 126
19 98 21 0.37 4 7 2 130 89 200
20 39 14 0.30 3 3 3 103 114 192
21 30 26 0.22 3 5 5 139 161 158
22 65 3 0.59 4 5 4 104 122 138
23 64 6 0.49 8 8 7 132 142 175
24 30 6 0.51 4 3 3 162 191 200
25 126 17 0.31 7 6 4 89 79 159
26 131 25 0.26 4 4 6 139 160 146
27 69 18 0.45 2 3 3 137 121 99
28 72 19 0.51 2 3 2 113 98 33
29 70 38 0.23 6 6 5 139 167 169
30 86 25 0.31 9 2 1 131 122 160
31 54 16 0.48 3 4 9 115 121 183
32 158 30 0.44 3 4 3 110 128 153
33 122 25 0.51 4 5 3 97 94 104
34 157 17 0.43 4 5 2 56 65 87
Mean  SEM 85  10 19  2.1 0.40 0.02 4 0.5 4  0.4 4  0.5 116 6 122 9 146 11
Total (mean  SEM) 206  36 21  1.9 0.37 0.02 5 0.4 6  0.5 5  0.4 106 5 117 6 137 7
LVEDVI, Left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index.
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Relationship Between Plasma BNP and Serum
Products of Type I and Type III Collagen
From baseline to month 1, plasma BNP decreased in
both groups of patients but was significantly higher (P
.001) in group 1 patients than in group 2, and the greater
difference between groups occurred at day 3 (326  58
pg/mL vs 85  58 pg/mL). Individual values of plasma
BNP at each time point of measurement are presented in
Table 2.
A significant linear relationship between BNP and
ICTP occurs at day 1 and day 3 in group 1 patients but
not in group 2 (Table 3). We further calculated the partial









Month 1Day 1 Day 3 Month 1
2 3 2 94 63 33
3 4 3 40 15 62
3 3 4 61 31 49
3 3 4 60 28 53
4 4 7 77 46 40
2 2 2 72 46 36
7 6 6 65 39 40
5 3 4 70 41 42
3 6 4 69 48 30
2 4 2 65 39 41
2 2 2 79 46 42
4 6 4 108 63 42
4 5 5 74 48 35
4 3 5 57 32 43
4 2 3 89 64 28
6 7 6 65 44 32
2 2 5 74 42 43
3.4 0.4 3.9 0.4 4  0.3 72  4 43  3 41  2
2 3 2 61 29 53
3 4 4 41 18 56
2 3 4 60 33 44
2 3 3 51 33 34
4 4 3 24 10 56
4 5 5 42 15 64
3 4 3 57 20 64
4 4 5 65 38 41
2 6 3 57 31 45
1 2 3 58 33 43
4 2 2 65 35 46
6 7 5 68 29 57
2 4 3 54 24 55
3 2 6 68 39 42
2 2 3 45 26 43
3 6 3 40 18 55
3 3 3 68 26 62
2.8 03 3.7 0.4 3.5  0.3 54  3 27  2 51  2.1
3.1 0.2 3.8  0.3 3.7  0.2 63  3 35  2.3 46 1.7
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SPECT infarct size and severity (Table 3) and found that
the relationship remained significant in group 1 patients
and not significant in group 2 patients. No relationship
was observed between BNP and PICP as well as PIIINP
in both groups of patients.
Predictors of 1-Month LV Remodeling
Univariate linear regression analysis of variables
potentially responsible for 1-month LV dilation is pre-
sented Table 4. On stepwise multiple linear regression
analysis, sustained pattern of high plasma BNP release,
baseline values of LV volume/mass index, and SPECT
infarct size emerged as independent predictors of
1-month LV remodeling (Table 5). The power of a
clinical-serum model and a clinical-imaging model was
also tested in hierarchic order (clinical-imaging model
first, then clinical-serum model) to predict 1-month LV
dilation. The R2 change obtained by the addition of the
clinical-serum model was significant (R2 change, 0.305
[from 0.173 to 0.478]; P  .004) (Table 6).
Interaction of ICTP on Relationship Between
Pattern of Plasma BNP Release Early After AMI
and Time Course of LVEDVI
Repeated-measures analysis showed that serum
changes from baseline to day 3 of ICTP, but not of PICP
and PIIINP, significantly interact with the relationship
between serial changes in LV volumes from baseline to
month 1 and different pattern of plasma BNP release
early after AMI (F  4.87, P  .03).
DISCUSSION
Study Findings
This study shows that (1) in the presence of similar
SPECT infarct size and severity, only higher ICTP levels
discriminate patients with or without sustained BNP
release early after AMI with regard to the pattern of
collagen metabolism; (2) only in patients with sustained
BNP release, serum ICTP during the first 3 days after
reperfused AMI is significantly related to concurrent
values of BNP and interacts with the relationship be-
tween BNP and 1-month LV dilation; and (3) sustained
BNP release and LV volume/mass ratio (a marker of wall
tension) are the two most important predictors of early
postinfarction LV dilation. These findings exclude that
combined BNP and ICTP increases are just the joint
consequence of larger and more severe infarctions. Our
results would support the hypothesis that sustained BNP
could be not just a marker but also a potential modulator
of LV remodeling through a favoring effect on ECM
degradation.
Comparison with Previous Studies
ECM remodeling plays a key role in postinfarc-
tion LV remodeling.7 However, the relationship be-
tween BNP and surrogate markers of ECM remodeling
in AMI patients is poorly understood. Tziakas et al8
showed a significant association between circulating
levels of N-terminal pro–B-type natriuretic peptide
and metalloproteinases (MMPs) in early and late
postinfarction remodeling. Squire et al9 reported a
correlation between MMP-9 levels and N-terminal
pro–B-type natriuretic peptide and between MMP-9
levels and echocardiographic LV dilation in patients
soon after AMI. Magga et al10 showed a significant
relationship between BNP and serum products of type
I collagen after AMI, and they suggest a possible
regulatory role of BNP on ECM degradation. In
patients with LV remodeling, we observed an increase
in BNP and type I collagen turnover, which was
apparently not influenced by enzymatic and echocar-
diographic estimates of infarct extent.11 Differently
from that report, in the present study we also examined
the turnover of soft-tissue type III collagen, as as-
sessed by changes in PIIINP. Changes in PIIINP have
been shown to be induced by AMI in humans26 and
may reflect both synthesis and degradation of soft-
tissue collagen,27 whereas PICP reflects synthesis and
ICTP degradation of bone-tissue collagen (type I).27,28
We observed that only higher circulating levels of
ICTP, which represent collagen degradation,28 dis-
criminate patients with or without sustained BNP
Figure 2. Changes in LVEDVI, LVESVI, and LVEF from
baseline to first month () in the 2 groups with and without
sustained plasma BNP release. *P .01 between groups; †P
.05 between groups.
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release early after AMI with regards to the pattern of
collagen metabolism. A possible explanation for this
finding is that in the presence of high concentrations of
BNP, there is increased MMP activity and ECM
degradation.5 Another novel point of this study is that
we used Tc-99m sestamibi gated SPECT to accurately
evaluate the influence of both infarct size and infarct
severity on BNP and collagen degradation. In the
setting of reperfusion the limitations of enzymatic
estimates of infarct dimensions are particularly impor-
tant.12,13 Similarly, there are major problems in defin-
ing the extent of infarction by use of methods based on
wall motion abnormalities.14,15 Conversely, Tc-99m
sestamibi SPECT infarct size measurements have been
shown to be reliable and have been accepted as
surrogate endpoints for studies comparing different
therapeutic strategies in AMI patients.16,17,29 We also
considered infarct severity, which is related to infarct
transmurality and therefore has implications for LV
remodeling.18,19
Figure 3. Serial changes in plasma PIIINP (A), ICTP (B), and PICP (C) levels in the 2 groups with
and without sustained plasma BNP release. *P  .01 between groups; †P  .05 versus baseline.
Table 3. Correlation between BNP and ICTP in patients with (group 1) or without (group 2) sustained plasma
BNP release and partial correlation coefficients between BNP and ICTP after controlling for SPECT measures of
infarct size and severity
Day 1 Day 3 Month 1
r P value r P value r P value
Correlation coefficients between BNP and ICTP
in patients with (group 1) or without
(group 2) sustained plasma BNP release
Group 1 0.57 .002 0.79 .01 0.33 .14
Group 2 0.5 .85 0.17 .52 0.35 .17
Partial correlation coefficients between BNP
and ICTP after controlling for SPECT
measures of infarct size and severity
Group 1 0.56 .02 0.77 .001 0.31 .25
Group 2 0.3 .92 0.24 .44 0.37 .19
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Plasma BNP Release, Collagen Degradation, ECM
Remodeling, and LV Remodeling
Even in patients with low LVEF after AMI, progres-
sive LV dilation is not always observed.30 A number of
factors other than infarct size probably contribute to
prevent LV dilation in these subjects.30-34 In this study
patients with sustained release of BNP early after AMI
and those without sustained release of BNP had similar
SPECT infarct size and severity. This is not surprising
because BNP may reflect the size or severity of the
ischemic insult even when myocardial necrosis has not
occurred.35 Accordingly, our patients with sustained
BNP release had longer symptom-to-balloon time and
greater impairment of LV function and more frequently
had multivessel disease as compared with patients with-
out sustained BNP release. For the same reason, we
observed that baseline values of plasma BNP did not
correlate with SPECT infarct size.
In our group of patients with sustained high BNP
and serum ICTP levels early after AMI, LV dilation
occurred at month 1 after index AMI. Of note, serum
increase in ICTP release during the early stage of index
AMI (from day 1 to day 3) significantly interacts with the
relationship between pattern of BNP release and subse-
quent LV dilation. To our knowledge, this interaction has
not been reported previously in AMI patients. The
patients with sustained BNP release show higher base-
line values of LV volume–mass ratio and shorter values
of mitral DT, which are markers of increased wall
tension,30 as well as LV filling pressure.36 Furthermore,
we found the sustained pattern of BNP release and the
LV volume–mass ratio to be the 2 most important
predictors of 1-month LV dilation. We also determined
how well a clinical-serum model performs when a
clinical-imaging model has already been taken into
account. Although the results of this observational study
are associative findings in a small patient population,
they are suggestive for generating the following hypoth-
esis. Because higher concentrations of BNP are likely
needed to induce ECM degradation,5 it is possible that
sustained high BNP level early after AMI might be
potentially harmful by allowing greater type I collagen
degradation, as well as consequent LV dilation, under the
effect of mechanical force.37 Thus MMP inhibitors have
the potential for postinfarction LV dilation prevention.38
Study Limitations
Temporal changes in serum levels of procollagens
are only surrogate markers of ECM remodeling; how-
ever, the biochemical method we used has been validated
by other groups.39 Several strategies currently used to
prevent remodeling after myocardial infarction, such as
angiotensin-converting enzyme inhibitors with or with-
out aldosterone antagonists, 	-blockers, and angiotensin
II receptor blockers, exert pleiotropic effects that can
potentially affect collagen turnover.40 However, there
were no differences in treatment between the 2 study
groups. It must be acknowledged that magnetic reso-
nance imaging via delayed contrast enhancement is
probably more accurate than Tc-99m sestamibi SPECT
Table 4. Univariate linear regression of predictors of
1-month LV dilation
Variable B SE P value
Age 0.09 0.24 .71
Sex 7.46 7.05 .29
Symptom-to-balloon time 2.09 1.61 .20
Anterior infarct location 4.54 6.72 .50
Pattern of BNP release 14.15 4.92 .007
DT 0.13 0.06 .05
LV volume–mass ratio 31.74 14.66 .03
SPECT infarct size 0.50 0.24 .04
SPECT infarct severity 27.56 19.44 .16
DT, Wave deceleration time of early transmitral flow; BNP, brain
natriuretic peptide.




B SE P value
Pattern of BNP release 18.24 4.93 .001
LV volume–mass ratio 38.05 14.30 .01
SPECT infarct size 0.44 0.20 .03
Table 6. Multivariate analysis: Clinical-imaging and





R2 R2 change P value
1° Step: Clinical-imaging 0.17 — .39
2° Step: Clinical-serum 0.48 0.31 .004
The clinical-imaging model comprises infarct anterior location,
symptom-to-balloon time, LV volume/mass index, SPECT infarct
size, and SPECT infarct severity. The clinical-serum model com-
prises infarct anterior location, symptom-to-balloon time, LV
volume/mass index, pattern of BNP release, and serum ICTP.
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in the assessment of small infarction and infarct trans-
murality.41 However, the large number of studies based
on Tc-99m sestamibi SPECT infarct size still justifies the
use of this approach that offers major advantages in
terms of ease and wide availability. Finally, this study
included only patients who had LV systolic dysfunction
(LVEF 40%) for a first ST–segment elevation AMI
and who were treated with percutaneous coronary inter-
vention. Whether our results can be extrapolated to the
broad population of AMI patients remains to be shown.
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